Black Diamond Therapeutics changes Chairman; Robert Ingram resigns, Mark Velleca appointed

Black Diamond Therapeutics, Inc.

Robert A. Ingram resigned as Chairman and Board member effective Dec 13, 2022; no disagreement with company.
Mark A. Velleca, M.D., Ph.D. appointed Chairman of the Board on Dec 15, 2022.
Board size reduced from 10 to 9 members upon Ingram's resignation.
Velleca has been a board member since Aug 2021, formerly CEO of G1 Therapeutics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert A. Ingram

Chairman of the Board

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2022-12-13
Successor: Mark A. Velleca
Filed: December 19, 2022, 6:59 PM ET

On December 13, 2022, Robert A. Ingram notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position of Chairman of the Board

Appointed

Mark A. Velleca

Chairman of the Board

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2022-12-15
Filed: December 19, 2022, 6:59 PM ET

On December 15, 2022, upon the recommendation of the NCG Committee, the Board appointed current Board member Mark A. Velleca, M.D., Ph.D. to serve as Chairman of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert A. Ingram resigned as Chairman of the Board at Black Diamond Therapeutics, Inc..

Action: resigned
Role: Chairman of the Board

Exact text from the filing

On December 13, 2022, Robert A. Ingram notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position of Chairman of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark A. Velleca was appointed as Chairman of the Board at Black Diamond Therapeutics, Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

On December 15, 2022, upon the recommendation of the NCG Committee, the Board appointed current Board member Mark A. Velleca, M.D., Ph.D. to serve as Chairman of the Board.

View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-128050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.